Lamotrigine as an Add-on Treatment for Depersonalization Disorder: A Retrospective Study of 32 Cases

@article{Sierra2006LamotrigineAA,
  title={Lamotrigine as an Add-on Treatment for Depersonalization Disorder: A Retrospective Study of 32 Cases},
  author={Mauricio Sierra and Dawn L. Baker and Nick Medford and Emma J. Lawrence and Maxine X. Patel and Mary L. Phillips and Anthony S. David},
  journal={Clinical Neuropharmacology},
  year={2006},
  volume={29},
  pages={253-258}
}
Objectives: Depersonalization disorder (DPD) is a chronic condition characterized by the persistent subjective experience of unreality and detachment from the self. To date, there is no known treatment. Lamotrigine as sole agent was not found to be effective in a previous small double-blind, randomized crossover trial. However, evidence from open trials suggests that it may be beneficial as an add-on medication with antidepressants. Methods: We report here an extended series of 32 patients with… 
View on Wolters Kluwer
ncbi.nlm.nih.gov
29 Citations
Highly Influential Citations
1
Background Citations
7
Methods Citations
1
Results Citations
1

29 Citations

A Case of Depersonalization with Treatment-resistant Depression Successfully Treated with Sertraline-lamotrigine Combination.

It is suggested that augmentation of sertraline with lamotrigine may have been the key ingredient in this patient's recovery of depersonalization with treatment-resistant depression.

Depersonalization disorder: pharmacological approaches

  • M. Sierra
  • Psychology, Biology
    Expert review of neurotherapeutics
  • 2008
A number of studies suggest that opioid receptor antagonists such as naltrexone and naloxone are useful in at least a subgroup of patients, and those neurotransmitter systems of relevance to depersonalization are known to play important inhibitory roles in the regulation of the stress response.

The efficacy of lamotrigine in a resistant case of depersonalization disorder.

A resistant case that responded to lamotrigine is presented, among the many psychoactive drugs studied, none of them has been shown to be the treatment of choice.

Use of Mixed Amphetamine Salts in a Patient with Depersonalization/Derealization Disorder.

  • Samuel R. Weber
  • Psychology, Medicine
    Innovations in clinical neuroscience
  • 2020
Given the lack of evidence-based interventions for patients with DDD, additional research into the potential benefit of using psychostimulants might be warranted.

Evidence-based treatment for Depersonalisation-derealisation Disorder (DPRD)

The limited data from randomised controlled trials on the pharmacotherapy and psychotherapy of DPRD demonstrates inconsistent evidence for the efficacy of lamotrigine, and no efficacy for other interventions.

Methylphenidate in depersonalization disorder: a case report.

A case that responded spectacularly to methylphenidate is presented, with virtually no evidence, and among the many psychoactive drugs studied, none of them has been shown to be the treatment of choice.

Treatment of Depersonalization Disorder With Repetitive Transcranial Magnetic Stimulation.

The case of a 30-year-old man with major depressive disorder and DPD who did not respond to pharmacotherapy is presented, and there was a significant reduction in his depersonalization symptoms after the patient was treated with low frequency rTMS to the right DLPFC followed by high frequency r tms to the left DLP FC.

Lamotrigine Uses in Psychiatric Practice-Beyond Bipolar Prophylaxis a Hope or Hype?

Level of evidence supporting the use of LAM in off-label indications is highly variable, and hence, sound clinical judgment is necessary for its proper use and placement in real-life psychiatric practice and psychopharmacotherapy algorithms.

Depersonalization disorder

Greater understanding of the clinical characteristics of this disorder will improve the reliability of diagnosis and aid the development of neurobiological and psychological models for empirical testing.

El metilfenidato en el trastorno por despersonalización: a propósito de un caso

A case that responded spectacularly to methylphenidate is presented, with virtually no evidence, and among the many psychoactive drugs studied, none of them has been shown to be the treatment of choice.

References

SHOWING 1-10 OF 42 REFERENCES

Treatment of depersonalization disorder with clomipramine

Fluoxetine therapy in depersonalisation disorder: Randomised controlled trial

Fluoxetine was not efficacious in treating depersonalisation disorder, despite the commonly reported clinical use of serotonin reuptake inhibitors for this condition.

A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder

Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study.

Lamotrigine might have antidepressive properties in unipolar patients and may accelerate onset of action when given in combination with typical antidepressants.

Feeling unreal: a depersonalization disorder update of 117 cases.

The characteristics of depersonalization disorder found in this sample, the largest described to date, are in good accord with previous literature, and the study highlights the need for novel therapeutic approaches to treat depersonALization disorder.

Depersonalisation disorder: clinical features of 204 cases

Depersonalisation disorder is a recognisable clinical entity but appears to have significant comorbidity with anxiety and depression and research into its aetiology and treatment is warranted.

Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder.

Chronic depersonalization following illicit drug use: a controlled analysis of 40 cases.

Drug-induced DP does not appear to represent a distinct clinical syndrome, and the neurocognitive mechanisms of the genesis and maintenance of DP are likely to be similar across clinical groups, regardless of precipitants.

Treatment of Depersonalization with Serotonin: Reuptake Blockers

The chronicity of illness and lack of prior response to a variety of treatments in these patients highlights the positive outcome with this treatment and issues are raised regarding the current hierarchical exclusion of depersonalization disorder in the presence of obsessive-compulsive and panic disorders.

The Cambridge Depersonalization Scale: a new instrument for the measurement of depersonalization.

The Cambridge Depersonalization Scale is meant to capture the frequency and duration of depersonalized symptoms over the 'last 6 months' and showed high internal consistency and good reliability, and can be profitably used in both clinical and neurobiological research.